Tumor-associated macrophages (TAM) interact with cancer
and stromal
cells and are integral to sustaining many cancer-promoting features.
Therapeutic manipulation of TAM could therefore improve clinical outcomes
and synergize with immunotherapy and other cancer therapies. While
different nanocarriers have been used to target TAM, a knowledge gap
exists on which TAM pathways to target and what payloads to deliver
for optimal antitumor effects. We hypothesized that a multipart combination
involving the Janus tyrosine kinase (JAK), noncanonical nuclear factor
kappa light chain enhancer of activated B cells (NF-κB), and
toll-like receptor (TLR) pathways could lead to a highly active myeloid
therapy (HAMT). Thus, we devised a screen to determine drug combinations
that yield maximum IL-12 production from myeloid cells to treat the
otherwise highly immunosuppressive myeloid environments in tumors.
Here we show the extraordinary efficacy of a triple small-molecule
combination in a TAM-targeted nanoparticle for eradicating murine
tumors, jumpstarting a highly efficient antitumor response by adopting
a distinctive antitumor TAM phenotype and synergizing with other immunotherapies.
The HAMT therapy represents a recently developed approach in immunotherapy
and leads to durable responses in murine cancer models.